Dapagliflozin Therapy In Cardiac Surgery

PHASE4CompletedINTERVENTIONAL
Enrollment

178

Participants

Timeline

Start Date

November 11, 2022

Primary Completion Date

June 1, 2024

Study Completion Date

June 1, 2025

Conditions
Diabetes Mellitus, Type 2Cardiac Surgery
Interventions
DRUG

Dapagliflozin

The patients is required to receive dapagliflozin(10mg, q.d.) at least for 3 days until 24 hours before the surgery. Then dapagliflozin will be discontinued and recovered as soon as the patient is able to take oral diet postoperatively. Dapagliflozin wil be ceased five days after surgery.

Trial Locations (1)

100037

National Clinical Research Center for Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing

All Listed Sponsors
lead

China National Center for Cardiovascular Diseases

OTHER_GOV